Project Grant R01CA316861
Award Date 8/27/26
Completion Date 7/31/31
Dollars Obligated $591K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Puerto Rico
Similar Awards
- The National Cancer Institute awarded the University of Hawaii $555,703 on August 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to identify biological mechanisms and risk factors contributing to the progression of ductal carcinoma in situ (DCIS) to invasive breast cancer among Asian American and Native Hawaiian/Pacific Islander (AANHPI) populations. The research addresses a clinical gap: fewer than 50 percent of DCIS patients progress to invasive cancer, yet no...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $427,249 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate molecular profiles and biomarkers associated with penile squamous cell carcinoma (PSCC) disparities across geographically distinct patient populations. The research compares molecular profiles across 350 primary tumors from diverse geographic areas to identify biological causes underlying the...
- The National Cancer Institute awarded University of Miami $322,563 on September 23, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate racial disparities in breast cancer risk and gene expression by examining the roles of genetic and lifestyle factors. The recipient will recruit 250 African Zambian women with pathologically confirmed breast cancer at the Cancer Disease Hospital in Lusaka, Zambia, collect clinical and lifestyle data, obtain tumor tissue...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $717,715 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a multi-ancestry genome-wide association study of mammographic density phenotypes and their genetic and nongenetic determinants in over 120,000 multiethnic women. The project addresses the genetic basis of mammographic density—a strong and common breast cancer risk factor that reduces screening...
- The National Cancer Institute awarded the University of Pittsburgh $649,620 on May 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to examine Medicare Advantage plan impacts on cancer care access, quality, and outcomes for older adults. The project investigates whether Medicare Advantage's limited provider networks create barriers to timely specialty care for patients with the four most prevalent cancers—breast, colorectal, lung, and prostate. The research employs...
- The National Cancer Institute awarded the University of Miami $522,368 on August 11, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate how RNA polymerase II bypasses transcription-blocking lesions caused by ultraviolet radiation and the role of transcription-coupled nucleotide excision repair (TC-NER) in this process. The research aims to understand how the acetyltransferase P300 regulates RNA polymerase II stalling at UV-induced DNA lesions, how its...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded New York University $701,574 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate APOBEC3-induced mutagenesis in cancer development and therapy resistance. The funded research develops experimental and bioinformatics methods to track de novo generation of specific mutational signatures (SBS2 and SBS13) induced by individual...
- The National Cancer Institute awarded Scripps Research Institute $744,054 on July 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop chemical inducers of proximity that antagonize FOXA1 function in prostate and breast cancer cells. The research synthesizes heterobifunctional compounds that recruit transcriptional co-regulators to FOXA1 to disrupt its essential transcriptional regulatory functions, and develops molecular glue degraders that induce FOXA1 degradation....
- The National Cancer Institute awarded the University of Texas at El Paso $573,746 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of N6-methyladenosine (M6A) modification in estrogen receptor activation and breast cancer progression. The research examines how M6A modification of enhancer RNAs facilitates phase-separated condensation of estrogen receptors, which is critical for assembling enhancer transcriptional machinery and regulating...
- The National Cancer Institute awarded The University of Texas Health Science Center at San Antonio $659,409 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to investigate genome maintenance mechanisms involving HELZ, a novel RNA helicase regulating R-loop resolution. The research focuses on R-loops, RNA-DNA hybrid structures critical for DNA double-strand break repair and genomic stability. R-loop dysregulation contributes to diseases including breast...